Jasper Therapeutics Q3 loss smaller than estimates

Reuters

Nov 10

<a href="https://laohu8.com/S/JSPR">Jasper Therapeutics</a> Q3 loss smaller than estimates

Overview

Jasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mln
Company completed $30 mln stock offering, extending cash runway through H1 2026

Outlook

Company plans to report final conclusions from investigation into BEACON study anomalies in Q4 2025
Company expects initial data from ETESIAN study in allergic asthma in Q4 2025
Jasper aims to complete dose selection for Phase 2b CSU study by mid-2026

Result Drivers

FINANCIAL POSITION - $30 mln stock offering completed, extending cash runway through H1 2026

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS	Beat	-$1.13	-$1.21 (7 Analysts)
Q3 Net Income		-$18.70 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Jasper Therapeutics Inc is $10.50, about 83% above its November 7 closing price of $1.78

Press Release: ID:nGNXyRBV4

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582790878"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582790878\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582790878?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582790878","market":"us","top_or_hot":-1,"title":"Jasper Therapeutics Q3 loss smaller than estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/JSPR\">Jasper Therapeutics</a> Q3 loss smaller than estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Jasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mln</p></li><li><p>Company completed $30 mln stock offering, extending cash runway through H1 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to report final conclusions from investigation into BEACON study anomalies  in Q4 2025</p></li><li><p>Company expects initial data from ETESIAN study in allergic asthma in Q4 2025</p></li><li><p>Jasper aims to complete dose selection for Phase 2b CSU study by mid-2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCIAL POSITION - $30 mln stock offering completed, extending cash runway through H1 2026</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$1.13</p></td><td><p>-$1.21 (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.70 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Jasper <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $10.50, about 83% above its November 7 closing price of $1.78</p></li></ul><p>Press Release: <span>ID:nGNXyRBV4</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jasper Therapeutics Q3 loss smaller than estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJasper Therapeutics Q3 loss smaller than estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/JSPR\">Jasper Therapeutics</a> Q3 loss smaller than estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Jasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mln</p></li><li><p>Company completed $30 mln stock offering, extending cash runway through H1 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to report final conclusions from investigation into BEACON study anomalies  in Q4 2025</p></li><li><p>Company expects initial data from ETESIAN study in allergic asthma in Q4 2025</p></li><li><p>Jasper aims to complete dose selection for Phase 2b CSU study by mid-2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCIAL POSITION - $30 mln stock offering completed, extending cash runway through H1 2026</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$1.13</p></td><td><p>-$1.21 (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.70 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Jasper <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $10.50, about 83% above its November 7 closing price of $1.78</p></li></ul><p>Press Release: <span>ID:nGNXyRBV4</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0HG:1","article_id":"2582790878","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582790878","pubTimestamp":1762780105,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jasper Therapeutics Q3 loss smaller than estimatesOverviewJasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mlnCompany completed $30 mln stock offering, extending cash runw","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","JSPR":"Jasper Therapeutics"},"translate_title":"Jasper Therapeutics第三季度亏损小于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JSPR":0.9},"content_text":"Jasper Therapeutics Q3 loss smaller than estimatesOverviewJasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mlnCompany completed $30 mln stock offering, extending cash runway through H1 2026OutlookCompany plans to report final conclusions from investigation into BEACON study anomalies  in Q4 2025Company expects initial data from ETESIAN study in allergic asthma in Q4 2025Jasper aims to complete dose selection for Phase 2b CSU study by mid-2026Result DriversFINANCIAL POSITION - $30 mln stock offering completed, extending cash runway through H1 2026Key DetailsMetricBeat/MissActualConsensus EstimateQ3 EPSBeat-$1.13-$1.21 (7 Analysts)Q3 Net Income-$18.70 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Jasper Therapeutics Inc is $10.50, about 83% above its November 7 closing price of $1.78Press Release: ID:nGNXyRBV4For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}